Overview

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions

Status:
Not yet recruiting
Trial end date:
2021-12-05
Target enrollment:
Participant gender:
Summary
Objective - Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical